How Endpoint Definitions and Ascertainment Methods Can Influence Clinical Trial Results
European Journal of Cardio-Thoracic Surgery · 10.03.2026 · 68 (3)
DOI: 10.1093/ejcts/ezag128 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 25.03.2026. Verfasst von Bjorn Redfors. Beteiligte Einrichtung: Department of Population Health Sciences, Weill Cornell Medicine, New York, NY 10022, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Clinical trial end-points are often treated as fixed and objective entities assumed to reflect an underlying biological truth. In practice, however, both the definition of an end-point and the methods used to ascertain it can exert a powerful influence on observed event rates, treatment comparisons, and ultimately on trial interpretation. These influences are particularly salient in cardiovascular trials, where composite end-points, adjudicated clinical events, and biomarker-based definitions are common. Failure to recognize how end-point definitions and ascertainment strategies shape trial results risks drawing conclusions that reflect methodological choices as much as true treatment effects or patient risk. End-point definitions can substantially alter the observed incidence of clinical events, with downstream consequences for both statistical power and clinical interpretation. More inclusive or liberal definitions inevitably increase event counts, whereas restrictive definitions reduce them. This effect is particularly consequential in composite end-points, where one component can numerically dominate the composite purely because of how it is defined. Procedural myocardial infarction (MI) provides a clear example familiar to cardiothoracic surgeons, as its definition has varied widely across contemporary revascularization trials. When stricter biomarker thresholds or more stringent criteria are applied, MI rates appear lower than when more liberal definitions are used, even within similar patient populations.1
Autor:innen und Institutionen
- Department of Population Health Sciences, Weill Cornell Medicine, New York, NY 10022, United States.
ORCID-Profile: Bjorn Redfors
Zitieren
APA
Redfors, B. (2026). How Endpoint Definitions and Ascertainment Methods Can Influence Clinical Trial Results. European Journal of Cardio-Thoracic Surgery, 68(3). https://doi.org/10.1093/ejcts/ezag128
Vancouver
Redfors B. How Endpoint Definitions and Ascertainment Methods Can Influence Clinical Trial Results. European Journal of Cardio-Thoracic Surgery. 2026;68(3). doi:10.1093/ejcts/ezag128
BibTeX
@article{Redfors2026,
author = {Redfors, Bjorn},
title = {How Endpoint Definitions and Ascertainment Methods Can Influence Clinical Trial Results},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2026},
volume = {68},
number = {3},
doi = {10.1093/ejcts/ezag128}
}
EUVIMED